Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TY-9591 versus osimertinib for EGFR-mutant non-small cell lung cancer with brain metastases
CTR20231808Phase 2Active
- Sponsor
- TYK Medicines
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of asandeutertinib in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by TYK Medicines. Primary endpoints: Intracranial objective response rate and Intracranial progression-free survival. Started Aug 2023; status: active.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on CTR20231808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231808.